One-Liner
A patient-owned outcome-tracking app for the 900–4,500 people dosed with approved cell and gene therapies, giving them cohort-compared 5-year outcome curves — a consumer product sold B2B2C through 80+ Cell & Gene Therapy treatment centers.
AI Thinking Process
50+ US/EU CGT approvals by 2025–2026. Manufacturer REMS registries are extract-and-send; patients never see cohort data. A patient dosed with Casgevy in 2024 cannot compare their 5-year outcomes to the global cohort of ~900 dosed patients.
Scale Shift: institutional post-market registry run by manufacturer → personal outcome-tracking app owned by the patient. Patient logs self-reported symptoms, lab results, HealthKit biometrics. Gets cohort-compared outcome curves.
Folia Health (PRO broadly), PicnicHealth (rare-disease records), Ciitizen (acquired by Invitae). Gene-therapy specific cohort dashboard doesn't exist as consumer product — manufacturers run own registries but not patient-visible.
Gene-therapy patient populations 50–3,000 per approval. Consumer front-end CAC in 900-person global cohort is financially absurd unless acquisition happens inside the hospital at treatment time — B2B2C sale to 80 CGT treatment centers.
WHO: patient dosed with approved CGT + CGT center director (dual-sided). CURRENT: patient receives paper post-dose schedule and REMS card; enrolls in manufacturer registry at dose; never sees cohort data again. WHY-SURPRISED: $2M–$4M per dose treatments yet the patient generating the outcome data has zero visibility into how their cohort performs.
Conviction 40%. Biggest worry: HIPAA plus state genetic-privacy laws. Consumer acquisition happens inside 80 hospitals — a grind. But B2B2C through CGT centers may be tractable.
MyLynx (cell-therapy patient tracking, Series A $9M 2024): targets CGT centers as customer. Memorial Sloan Kettering and Dana-Farber are reference customers. Handles patient outreach, AE capture, post-dose monitoring. Can extend to cohort-comparison in one product cycle. Pass 1 missed this.
Killed in deepening. MyLynx holds the CGT-center channel (MSK, Dana-Farber). Patient-held cohort dashboard angle is a narrow wedge but distribution channel is closed. HIPAA + GIPA compliance capital-intensive without venture scale. Conviction dropped 40% → 35%, below Pass 2 threshold.
Kill Reason
MyLynx (Series A $9M 2024) targets CGT treatment centers as its customer, with Memorial Sloan Kettering and Dana-Farber as reference accounts. MyLynx handles patient outreach, adverse-event capture, and post-dose monitoring — and can extend to cohort-comparison dashboards in one product cycle. With MyLynx holding the CGT-center channel, the distribution path is effectively closed. HIPAA plus CA GINA and Illinois GIPA genetic-privacy compliance is capital-intensive without venture scale.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.